secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-09-19T23:59:59+00:00
Accession:  0001493152-25-014293
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi eliminates CLO role; W. Pizarro Campbell departs Oct 17, 2025
--------------------------------------------------------------------

- CLO position eliminated; Campbell's employment terminated Oct 17, 2025 as part of cost-reduction initiatives; no disagreement cited.
- Campbell receives severance of $212,500 paid over six months, plus potential $85,000 bonus tied to Nova Cell transaction before Oct 31, 2025.
- Campbell enters six-month consulting agreement at $250/hr (max 20 hrs/mo) starting Oct 18, 2025.
- CFO Andrew Jackson appointed as Corporate Secretary effective Oct 17, 2025.
- Separation agreement includes standard release, confidentiality, and non-disparagement clauses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225014293/0001493152-25-014293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225014293/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-014293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer